Navigation Links
A Slow Economy and High Development Costs to Drive Rise in Pharmaceutical Outsourcing to Contract Research Organizations
Date:8/22/2012

FARMINGTON, Conn., Aug. 22, 2012 /PRNewswire-iReach/ -- It's a well known data point that while the pills a doctor prescribes may cost pennies each to manufacture, the first pill cost many millions of dollars to research, develop, test, and certify. Along the way, many routes are pursued and ultimately dropped when they fail to yield marketable results. One way drug manufacturers can lower their costs and increase their output is to outsource stages of the process to Contract Research Organizations (CROs) that specialize in drug discovery, hit confirmation, and lead optimization.

(Photo: http://photos.prnewswire.com/prnh/20120822/CG61248)

Global Information Inc, in cooperation with its premium market research publishing partners, is pleased to announce three new market research reports exploring the market for CROs, providing valuable data for market participants – both CROs and pharmaceutical companies themselves – as well as investors, reporters, analysts, and regulators.

Contract Research Organization Market in the US 2011-2015

TechNavio's analysts forecast the Pharmaceutical Contract Research Organization market in the US will grow at a CAGR of 9.7 percent between 2011 and 2015. One of the key factors contributing to this is the increasing outsourcing of R&D activities. The CRO market in the US has also been witnessing the trend of emerging outsourcing destinations. However, the shortage of CRO staff could pose a challenge to the growth of this market.

TechNavio's report, The Contract Research Organization Market in the US 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the USA region; it also covers the Contract Research Organization market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Charles River Laboratories International Inc., Covance Inc., Pharmaceutical Product Development Inc., Quintiles Transnational Corp.

An Executive Summary, table of contents, and free sample are available from GII at http://www.giiresearch.com/report/infi248653-contract-research-organization-market-us.html

Medical Devices Contract Research Organizations - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018

GlobalData's new market research report, Medical Devices Contract Research Organizations - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018, provides key data, information and analysis on the global medical devices CRO market. This report outlines the current market and competitive landscapes, gives market trend information for the medical devices CRO market, and provides comprehensive information on the key trends affecting the market, as well as key analytical content. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

An Executive Summary of this analysis, full table of contents, and a free sample of the full report are available at http://www.giiresearch.com/report/gd244312-medical-devices-contract-research-organizations.html

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market

The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).

Since the last edition of Kalorama's Report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced. Kalorama Information's Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.

An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/kl241549-outsourcing-drug-discovery-contract-research.html

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia, Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NationsHealth, Inc. Boosts Arizona Economy With Business Expansion
2. Telemedicine, Teleradiology, and Telemonitoring Look Like Winners in the New Healthcare Economy
3. New Report Shows Ohio Clinical Trials Benefit Patients, the Economy and Science
4. AdvaMed & BioOhio Discuss MedTech Impact on Ohios Economy, Job Creation
5. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
6. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor
9. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
10. Major Breakthrough in Hepatitis C Vaccine Development
11. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center ... recognizing the organization as a top behavioral service provider in the country. The ... quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... Vancouver, B.C., Canada (PRWEB) , ... December 06, ... ... Consultants (STC) announce the availability of the newly updated International Audit Protocol Consortium ... world use IAPC EHS audit protocols to understand the scope of their EHS ...
Breaking Medicine News(10 mins):